Boston Scientific announced a notable one-year revenue growth of 17.4% and a 24.2% increase in earnings per share, signaling robust performance despite a staggering 47.5% plunge in its stock price over the past year. The company faces ongoing challenges from tariff, supply-chain, and currency pressures, complicating its outlook even as it anticipates a solid 7.3% CAGR in the cardiovascular devices market. Jim Cramer has recommended holding the stock, which is currently trading at a 623% premium, reflecting investor interest bolstered by recent approvals of new medical devices.
“Boston Scientific · One-Year Revenue Growth · % · +17.4%”
“Boston Scientific · Average organic revenue growth · % · +15.7%”
“Boston Scientific · Annual growth in earnings per share · % · +24.2%”
“Boston Scientific · Free cash flow margin increase · percentage points · +9.1”
“Boston Scientific Corporation · has insiders that sold shares · multiple insiders · over the last year”
“Boston Scientific Corporation · insiders own · company stock · 0.2%”
“Jim Cramer · recommended holding · Boston Scientific Corporation”
“Jim Cramer · recommended holding · Boston Scientific Corporation · true”
“Boston Scientific · is · a prominent global player in cardiovascular technology”
“Boston Scientific · is expected to witness · a strong CAGR · 7.3%”
“Boston Scientific · shares have plunged · roughly 47.5%”
“Boston Scientific · received approval for · FARAPOINT nav-enabled PFA catheter”
